{"id":8936,"date":"2024-10-01T16:13:01","date_gmt":"2024-10-01T20:13:01","guid":{"rendered":"https:\/\/lifescivoice.com\/?p=8936"},"modified":"2024-10-01T16:13:01","modified_gmt":"2024-10-01T20:13:01","slug":"abbvies-parkinsons-drug-meets-phase-3-trial-goal","status":"publish","type":"post","link":"https:\/\/lifescivoice.com\/abbvies-parkinsons-drug-meets-phase-3-trial-goal\/","title":{"rendered":"AbbVie\u2019s Parkinson\u2019s Drug Meets Phase 3 Trial Goal"},"content":{"rendered":"<p>AbbVie has disclosed that its late-stage monotherapy prospect substantially decreased the impact of the condition in patients as contrasted with placebo on the same day that various medications used in the treatment of Parkinson&#8217;s disorder are being questioned left, right, and center.<\/p>\n<p>During the third phase of the TEMPO-1 experiment, two daily dosages of tavapadon, which is an oral dopamine receptor agonist, were evaluated. These doses were 5 mg and 15 mg. According to a statement, both arms significantly outperformed the placebo in terms of reducing disease burden at Week 26. This was determined by a composite score that included components of an industry assessment known as the Movement Disorder Society-Unified Parkinson&#8217;s Disease Rating Scale.<br \/>\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script> <ins class=\"adsbygoogle\" style=\"display: block; text-align: center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins> <script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><br \/>\nAccording to the press announcement issued by AbbVie, tavapadon not only achieved the main target, but it also achieved a secondary endpoint, which related to the betterment of patients&#8217; mobility in their day-to-day lives.<\/p>\n<p>According to AbbVie, the majority of the negative reactions were mild to moderate in intensity and were consistent with the results of previous clinical studies.<\/p>\n<p>A portion of tavapadon&#8217;s binding occurs at the D1 and D5 dopamine receptors, both of which are involved in the process of controlling motor activity. In addition to being explored as a monotherapy, it is also being tried in conjunction with levodopa, which is a biological counterpart to dopamine and is often used as an initial treatment for Parkinson&#8217;s disease.<br \/>\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script> <ins class=\"adsbygoogle\" style=\"display: block; text-align: center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins> <script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><br \/>\nAccording to the announcement issued by the pharmaceutical company, AbbVie intends to disclose the findings of a further phase 3 study of tavapadon later on in this year. This study is evaluating the drug&#8217;s efficacy as a monotherapy with a variable dosage.<\/p>\n<p>Following the acquisition of Cerevel Therapeutics for an astounding $8.7 billion, the pharmaceutical company was able to acquire tavapadon the previous year. Additionally, emraclidine, which is now being studied for its effectiveness in treating psychosis associated with Alzheimer&#8217;s disease and schizophrenia, is the second high-performing drug of that agreement. The selective positive allosteric modulator of muscarinic M4 belongs to the same category as Karuna Therapeutics&#8217; KarXT, which is now awaiting a decision from the FDA about its approval.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie has disclosed that its late-stage monotherapy prospect substantially decreased the impact of the condition in patients as contrasted with placebo on the same day that various medications used in the treatment of Parkinson&#8217;s disorder are being questioned left, right, and center. During the third phase of the TEMPO-1 experiment, two daily dosages of tavapadon, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8937,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[],"class_list":{"0":"post-8936","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-clinical"},"_links":{"self":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/8936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/comments?post=8936"}],"version-history":[{"count":1,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/8936\/revisions"}],"predecessor-version":[{"id":8938,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/8936\/revisions\/8938"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media\/8937"}],"wp:attachment":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media?parent=8936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/categories?post=8936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/tags?post=8936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}